EUVIMEDEUVIMED entdecken
Crossref

Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity

Lin Zhao, Ying Chen, Zhifeng Cheng, Dan Zhu, Qifu Li, Hanqing Cai, Yuan Hui, Qi Wang, Junfeng Han, Zongyou Cheng, Guiping Li, Shumei Zhong und 15 weitere

JAMA · 15.11.2026

DOI: 10.1001/jama.2026.24796 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, online erschienen am 15.11.2026. Verfasst von Lin Zhao und 26 weiteren Autor:innen. Beteiligte Einrichtung: Ministry of Education Key Laboratory of Metabolism and Molecular Medicine, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan Univ…. Die Arbeit nennt 21 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IMPORTANCE Obesity is a major health problem in China; more pharmacotherapy choices for long-term weight management are needed. OBJECTIVE To evaluate the efficacy and safety of once-weekly subcutaneous ribupatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, for weight loss in adults in China with overweight or obesity without diabetes. DESIGN, SETTING, AND PARTICIPANTS This multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial was conducted at 55 sites in China. From May to June 2024, adults without diabetes who had a body mass index of 28 or greater or 24 or greater with at least 1 weight-related comorbidity were enrolled, with final follow-up on June 20, 2025. INTERVENTIONS Participants were randomized to receive once-weekly subcutaneous ribupatide (target doses of 2 mg, 4 mg, or 6 mg) or matching placebo for 48 weeks, with dose escalation for up to 20 weeks and concomitant lifestyle intervention. MAIN OUTCOMES AND MEASURES The primary outcome was change in body weight from baseline to week 48, including percent change in body weight and the percentage of participants achieving at least 5% body weight reduction, analyzed under the treatment policy estimand. RESULTS Among 567 randomized participants (309 [54.5%] female; mean [SD] age was 34.4 [8.4] years, body weight was 93.0 [17.3] kg, and body mass index was 33.3 [4.5]), 514 (90.7%) completed the 48-week treatment period. Least-squares mean percentage changes in body weight at week 48 were −10.7%, −16.4%, and −17.7% with ribupatide 2, 4, and 6 mg, respectively, vs −1.4% with placebo. At week 48, the placebo-adjusted differences in percentage change in body weight were −9.3 (95% CI, −11.4 to −7.3) percentage points with ribupatide 2 mg, −15.0 (95% CI, −17.1 to −12.9) percentage points with ribupatide 4 mg, and −16.3 (95% CI, −18.4 to −14.2) percentage points with ribupatide 6 mg ( P < .001 for all). For at least 5% body weight reduction at week 48, the multiply imputed response rates were 68.1% (95% CI, 59.9% to 75.3%) for ribupatide 2 mg (97 of 142), 88.0% (95% CI, 81.3% to 92.6%) for ribupatide 4 mg (124 of 141), 85.7% (95% CI, 78.6% to 90.7%) with ribupatide 6 mg (121 of 141), and 16.0% (95% CI, 10.8% to 23.1%) with placebo (23 of 143). Placebo-adjusted differences for ribupatide 2, 4, and 6 mg were 52.0 (95% CI, 42.2 to 61.9), 72.0 (95% CI, 63.7 to 80.2), and 69.7 (95% CI, 61.1 to 78.3) percentage points, respectively (all P < .001). The most frequent treatment-emergent adverse events with ribupatide were gastrointestinal events, occurring in 47.9%, 58.2%, and 63.1% of participants receiving ribupatide 2 mg, 4 mg, and 6 mg, respectively, compared with 23.1% receiving placebo; most were mild to moderate in severity and few participants (0.7%) permanently discontinued study treatment because of adverse events. CONCLUSIONS AND RELEVANCE Among adults in China with overweight or obesity without diabetes, once-weekly subcutaneous ribupatide resulted in significantly greater weight loss at 48 weeks. Gastrointestinal adverse events were the most frequent tolerability findings. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT06396429

Autor:innen und Institutionen

  • Ministry of Education Key Laboratory of Metabolism and Molecular Medicine, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Endocrinology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Department of Cardiovascular Medicine, Peking University Third Hospital, Beijing, China.
  • Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Endocrinology, The Second Hospital of Jilin University, Changchun, China.
  • Department of Endocrinology, The First People's Hospital of Lianyungang, Lianyungang, China.

Zitieren

APA

Zhao, L., Chen, Y., Cheng, Z., Zhu, D., Li, Q., Cai, H., Hui, Y., Wang, Q., Han, J., Cheng, Z., Li, G., Zhong, S., Wang, J., Wang, L., Meng, C., Li, S., Su, H., Xu, Y., Zeng, M., …, & Li, X. (2026). Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity. JAMA. https://doi.org/10.1001/jama.2026.24796

Vancouver

Zhao L, Chen Y, Cheng Z, Zhu D, Li Q, Cai H, et al. Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity. JAMA. 2026. doi:10.1001/jama.2026.24796

BibTeX
@article{Zhao2026,
  author = {Zhao, Lin and Chen, Ying and Cheng, Zhifeng and Zhu, Dan and Li, Qifu and Cai, Hanqing and Hui, Yuan and Wang, Qi and Han, Junfeng and Cheng, Zongyou and Li, Guiping and Zhong, Shumei and Wang, Jinyang and Wang, Lianwei and Meng, Chao and Li, Shu and Su, Hongye and Xu, Yi and Zeng, Meifang and Zuo, Yue and Zhang, Lei and Wei, Wenhua and Wang, Lihao and Wang, Yike and Lv, Minzhi and Chen, Hong and Li, Xiaoying},
  title = {Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity},
  journal = {JAMA},
  year = {2026},
  doi = {10.1001/jama.2026.24796}
}
Kostenlos starten →